Progress in Pediatric Cardiology
Volume 24, Issue 1 , Pages 59-71 , November 2007

Nutrition in pediatric cardiomyopathy

References 

  1. Nugent AW, Daubeney PE, Chondros P, et al. The epidemiology of childhood cardiomyopathy in Australia. N Engl J Med. Apr 24 2003;348(17):1639–1646
  2. Lipshultz SE, Sleeper LA, Towbin JA, et al. The incidence of pediatric cardiomyopathy in two regions of the United States. N Engl J Med. Apr 24 2003;348(17):1647–1655
  3. Grenier MA, Osganian SK, Cox GF, et al. Design and implementation of the North American Pediatric Cardiomyopathy Registry. Am Heart J. 2000;139(2 Pt 3):S86–S95
  4. Boucek MM, Faro A, Novick RJ, et al. The Registry of the International Society of Heart and Lung Transplantation: Fourth Official Pediatric Report-2000. J Heart Lung Transplant. 2001;20:39–52
  5. Colan SD, Spevak PJ, Parness IA, et al. Cardiomyopathies. In:  Fyler DC editors. Nadas' Pediatric Cardiology. New York: Balfus and Hanley; 1992;
  6. Burch M, Siddiqi SA, Celermajer DD, et al. Dilated cardiomyopathy in children: determinants of outcome. Br Heart J. 1994;72:246–250
  7. Maron BJ, Tajik AJ, Ruttenberg HD, et al. Hypertrophic cardiomyopathy in infants: clinical features and natural history. Circulation. 1982;65(1):7–17
  8. Towbin JA, Bowles NE. The failing heart. Nature. Jan 10 2002;415(6868):227–233
  9. Thiene G, Becker AE, Buja LM, et al. Toward a cardiovascular pathology training report on the forum held in Vancouver, March 6, 2004, Society for Cardiovascular Pathology. Cardiovasc Pathol. Nov Dec 2005;14(6):312–319
  10. Boucek MM, Edwards LB, Keck BM, et al. The Registry of the International Society for Heart and Lung Transplantation: Sixth Official Pediatric Report-2003. J Heart Lung Transplant. 2003;22:636–652
  11. Bilgic A, Ozbarlas N, Ozkutlu S, et al. Cardiomyopathies in children: clinical, epidemiological and prognostic evaluation. Jpn Heart J. 1990;31:789–797
  12. Lipshultz SE. Ventricular dysfunction clinical research in infants, children and adolescents. Prog Pediatr Cardiol. Nov 4 2000;12(1):1–28
  13. Evans RW. Economic and social costs of heart transplantation. Heart Transplant. 1982;1:243–251
  14. Strauss A, Lock JE. Pediatric cardiomyopathy—a long way to go. N Engl J Med. Apr 24 2003;348(17):1703–1705
  15. Blecker U, Mehta DI, Davis R, et al. Nutritional problems in patients who have chronic disease. Pediatr Rev. 2000;21(1):29–32
  16. Karp RJ, Bachrach SJ, Moskowitz S. Malnutrition in chronic illness of childhood with special reference to pulmonary disease. Clin Chest Med. 1980;1(3):375–383
  17. Kelly DA. Nutrition and growth in patients with chronic liver disease. Indian J Pediatr. 1995;62(5):533–544
  18. Kohaut EC. Chronic renal disease and growth in childhood. Curr Opin Pediatr. 1995;7(2):171–175
  19. Yip R, Scanlon K. The burden of malnutrition: a population perspective. J Nutr. 2002;10:2043s–2046s[supplement]
  20. Franssen FM, Wouters EF, Schols AM. The contribution of starvation deconditioning and ageing to the observed alterations in peripheral skeletal muscle in chronic organ diseases. Clin Nutr. 2002;21(1):1–14
  21. Keusch GT. The history of nutrition: malnutrition, infection, and immunity. J Nutr. 2003;133(1):336s–340s
  22. Hughes WT, Price RA, Sisko F, et al. Protein–calorie malnutrition. A host determinant for Pneumocystis carnii. Am J Dis Child. 1974;128(1):44–52
  23. Miller TL, Awnetwant EL, Evans S, et al. Gastrostomy tube supplementation fo HIV-infected children. Pediatrics. 1995;96:696–702
  24. Al-Attar I, Orav EJ, Exil V, et al. Pedictors of cardiac morbidity and related mortality in children with acquired immunodeficiency syndrome. J Am Coll Cardiol. 2003;41(9):1598–1605
  25. Azevedo VM, Albanesi-Filho FM, Santos MA, et al. The impact of malnutrition on idiopathic dilated cardiomyopathy in children. J Pediatr (Rio J). 2004;80(3):211–216[Portuguese]
  26. Leitch CA. Growth, nutrition and energy expenditure in pediatric heart failure. Prog Pediatr Cardiol. 2000;11(3):195–202
  27. Miller TL, Orav EJ, Colan SD, Lipshultz SE. Nutritional status and cardiac mass and function in children infected with the human immunodeficiency virus. Am J Clin Nutr. Sep 1997;66(3):660–664
  28. Davos CH, Doehner W, Rauchhaus M, et al. Body mass and survival in patients with chronic heart failure without cachexia: the importance of obesity. J Card Fail. Feb 2003;9(1):29–35
  29. Horwich TB, Fonarow GC, Hamilton MA, MacLellan WR, Woo MA, Tillisch JH. The relationship between obesity and mortality in patients with heart failure. J Am Coll Cardiol. Sep 2001;38(3):789–795
  30. Dietary Reference Intakes for Calcium, Phosphorus, Magnesium, Vitamin D, Fluoride (1997). Dietary Reference Intakes for Thiamin, Riboflavin, Niacin, Vitamin B6, Folate, Vitamin B12 (1998). Dietary Reference Intakes for vitamin C, Vitamin E, Selenium, and Carotenoids (2000).Dietary Reference Intakes for Vitamin A, Vitamin K, Arsenic, Boron, Chromium, Copper, Iodine, Iron, Manganese, Molybdenum, Nickel, Silicon, Vanadium, and Zinc (2001). Dietary Reference Intakes for Energy, Carbohydrate, Fiber, Fat, Fatty Acids, Cholesterol, Protein, and Amino Acids (2002). Dietary Reference Intakes for Water, Potassium, Sodium, Chloride, and Sulfate (2004). Food and Nutrition Board, Institute of Medicine, National Academies of Sciences. Retrieved June 20, 2007 from http://www.nap.edu.
  31. Linde LM. Psychiatric aspects of congenital heart disease. Psychiatr Clin North Am. 1982;5:399–406
  32. Howard BV, Van Horn L, Hsia J, et al. Low-fat dietary pattern and risk of cardiovascular disease: the Women's Health Initiative Randomized Controlled Dietary Moification Trial. JAMA. Feb 8 2006;295(6):655–666
  33. Sparagna GC, Hickson-Bick DL, Buja LM, McMillin JB. A metabolic role for mitochondria in palmitate-induced cardiac myocyte apoptosis. Am J Physiol Heart Circ Physiol. Nov 2000;279(5):H2124–H2132
  34. Gudz TI, Tserng KY, Hoppel CL. Direct inhibition of mitochondrial respiratory chain complex III by cell-permeable ceramide. J Biol Chem. Sep 26 1997;272(39):24154–24158
  35. Okere IC, Young ME, McElfresh TA, et al. Low carbohydrate/high-fat diet attenuates cardiac hypertrophy, remodeling, and altered gene expression in hypertension. Hypertension. Dec 2006;48(6):1116–1123[Electronic publication 2006 Oct 23]
  36. Broqvist M, Arnqvist H, Dahlstrom U, Larsson J, Nylander E, Permert J. Nutritional assessment and muscle energy metabolism in severe chronic congestive heart failure: effects of long-term dietary supplementation. Eur Heart J. 1994;15:1641–1650
  37. Sole MJ, Jeejeebhoy KN. Conditioned nutritional requirements: therapeutic relevance to heart failure. Herz. 2002;27:174–179[PubMed SpringerLink]
  38. de Lorgeril M, Salen P. Diet as preventive medicine in cardiology. Curr Opin Cardiol. Sep 2000;15(5):364–370
  39. Keith M, Geranmayegan A, Sole MJ, et al. Increased oxidative stress in patients with congestive heart failure. J Am Coll Cardiol. May 1998;31(6):1352–1356
  40. Kris-Etherton PM, Harris WS, Appel LJ. American Heart Association. Nutrition Committee. Fish consumption, fish oil, omega-3 fatty acids, and cardiovascular disease. Circulation. Nov 19 2002;106(21):2747–2757[No abstract available. Erratum in: Circulation. 2003 Jan 28;107(3):512]
  41. Kaul N, Siveski-Iliskovic N, Hill M, Slezak J, Singal PK. Free radicals and the heart. J Pharmacol Toxicol Methods. Oct 1993;30(2):55–67
  42. Prasad K, Kalra J, Bharadwaj L. Cardiac depressant effects of oxygen free radicals. Angiology. Apr 1993;44(4):257–270
  43. Dhalla AK, Singal PK. Antioxidant changes in hypertrophied and failing guinea pig hearts. Am J Physiol. Apr 1994;266(4 Pt 2):H1280–H1285
  44. Gupta M, Singal PK. Higher antioxidative capacity during a chronic stable heart hypertrophy. Circ Res. Feb 1989;64(2):398–406
  45. Li RK, Sole MJ, Mickle DA, Schimmer J, Goldstein D. Vitamin E and oxidative stress in the heart of the cardiomyopathic Syrian hamster. Free Radic Biol Med. 1997;24:252–258
  46. Carlson D, Maass DL, White DJ, Tan J, Horton JW. Antioxidant vitamin therapy alters sepsis-related apoptotic myocardial activity and inflammatory responses. Am J Physiol Heart Circ Physiol. Dec 2006;291(6):H2779–H2789
  47. Montessuit C, Papageorgiou I, Campos L, Lerch R. Retinoic acids increase expression of GLUT4 in dedifferentiated and hypertrophied cardiac myocytes. Basic Res Cardiol. Jan 2006;101(1):27–35
  48. Palace VP, Khaper N, Qin Q, Singal PK. Antioxidant potentials of vitamin A and carotenoids and their relevance to heart disease. Free Radic Biol Med. 1999;26:746–761
  49. Miwa K, Kishimoto C, Nakamura H, et al. Serum thioredoxin and alpha-tocopherol concentrations in patients with major risk factors. Circ J. 2005;69:291–294
  50. The Heart Outcomes Prevention Evaluation Study Investigators. Vitamin E supplementation and cardiovascular events in high-risk patients. N Engl J Med. 2000;342:154–160
  51. Lonn E, Yusuf S, Hoogwerf B, et al. Effects of vitamin E on cardiovascular and microvascular outcomes in high-risk patients with diabetes: results of the HOPE study and MICRO-HOPE substudy. Diabetes Care. 2002;25:1919–1927
  52. Lonn E, Bosch J, Yusuf S, et al. Effects of long-term vitamin E supplementation on cardiovascular events and cancer: a randomized controlled trial. JAMA. 2005;293:1338–1347
  53. Mann JF, Lonn EM, Yi Q, et al. Effects of vitamin E on cardiovascular outcomes in people with mild-to-moderate renal insufficiency: results of the HOPE study. Kidney Int. 2004;65:1375–1380
  54. Dietary supplementation with n-3 polyunsaturated fatty acids and vitamin E after myocardial infarction: results of the GISSI-Prevenzione trial. Lancet. 1999;354:447–455
  55. Keith ME, Jeejeebhoy KN, Langer A, et al. A controlled clinical trial of vitamin E supplementation in patients with congestive heart failure. Am J Clin Nutr. 2001;73:219–224
  56. Azuma J, Sawamura A, Awata N. Usefulness of taurine in chronic congestive heart failure and its prospective application. Jpn Circ. 1992;56:95–99
  57. Schuller-Levis GB, Park E. Taurine: new implications for an old amino acid. FEMS Microbiol Lett. 2003;226:195–202
  58. Grimble RF, Jackson AA, Persaud C, Wride MJ, Delers F, Engler R. Cysteine and glycine supplementation modulate the metabolic response to tumor necrosis factor alpha in rats fed a low protein diet. J Nutr. 1992;122:2066–2073
  59. Schaffer SW, Allo S, Harada H, Mozaffari M. Potentation of myocardial ischemic injury by drug-induced taurine depletion. In:  Huxtable RJ,  Franconi F,  Giotti A editor. The biology of taurine. New York: Plenum Press; 1987;p. 151–158
  60. Kramer JH, Chovan JP, Schaffer SW. The effect of taurine on calcium paradox and ischemic heart failure. Am J Physiol. 1981;240:H238–H246
  61. Oudit GY, Trivieri MG, Khaper N, et al. Taurine supplementation reduces oxidative stress and improves cardiovascular function in an iron overload murine model. Circulation. 2004;109:1877–1885
  62. Kishi T, Okamoto T, Takahashi T, Goshima K, Yamagami T. Cardiostimulatory action of coenzyme Q homologues on cultured myocardial cells and their biochemical mechanisms. Clin Investig. 1993;71(8 Suppl):S71–S75
  63. Bentinger M, Dallner G, Chojnacki T, Swiezewska E. Distribution and breakdown of labeled coenzyme Q10 in rat. Free Radic Biol Med. Mar 1 2003;34(5):563–575
  64. Shindo Y, Witt E, Han D, Epstein W, Packer L. Enzymic and non-enzymic antioxidants in epidermis and dermis of human skin. Invest Dermatol. 1994;102:122–124
  65. Kitamura N, Yamaguchi A, Otaki M. Myocardial tissue level of co-enzyme Q10 in patients with cardiac failure. In:  Folkers K,  Yamamura Y editor. Biomedical and physical aspects of coenzyme Q. vol. 4:Amsterdam: Elsevier; 1984;p. 243–257
  66. Jameson S. Statistical data support prediction of death within 6 months on low levels of coenzyme Q10 and other entities. Clin Invest. 1993;71:S137–S139
  67. Hofman-Bang C, Rehnqvist N, Swedberg K, et al. Coenzyme Q10 as an adjunctive treatment of chronic congestive heart failure. The Q10 study group. J Card Fail. 1995;2:101–107
  68. Morisco C, Trimarco B, Condorelli M. Effect of coenzyme Q10 therapy in patients with congestive heart failure: a long-term multicentre randomised study. Clin Invest. 1993;71:S134–S136
  69. Watson PS, Scalia GM, Galbraith A, et al. Lack of effect of coenzyme Q10 on left ventricular function in patients with congestive cardiac failure. J Am Coll Cardiol. 1999;33:1549–1552
  70. Khatta M, Alexander BS, Krichten CM, et al. The effect of coenzyme Q10 in patients with congestive heart failure. Ann Intern Med. 2000;132:636–640
  71. Permanetter B, Rossy W, Klein G, et al. Ubiquinone (coenzyme Q10) in the long-term treatment of idiopathic dilated cardiomyopathy. Eur Heart J. 1992;13:1528–1533
  72. Soja AM, Mortenson SA. Treatment of congestive heart failure with Co-enzyme Q10 illuminated by meta-analysis of clinical trials. Mol Aspects Med. 1997;18:S159–S168[Suppl]
  73. de Lorgeril M, Salen P, Accominotti M, et al. Dietary and blood antioxidants in patients with chronic heart failure. Insights into the potential importance of selenium in heart failure. Eur J Heart Fail. 2001;3:661–669
  74. Guaiquil VH, Golde DW, Beckles DL, Mascareno EJ, Siddiqui MA. Vitamin C inhibits hypoxia-induced damage and apoptotic signaling pathways in cardiomyocytes and ischemic hearts. Free Radic Biol Med. 2004;37:1419–1429
  75. Fu YC, Chi CS, Yin SC, Hwang B, Chiu YT, Hsu SL. Norepinephrine induces apoptosis in neonatal rat cardiomyocytes through a reactive oxygen species-TNF alpha-caspase signaling pathway. Cardiovasc Res. 2004;62:558–566
  76. Rossig L, Hoffmann J, Hugel B, et al. Vitamin C inhibits endothelial cell apoptosis in congestive heart failure. Circulation. 2001;104:2182–2187
  77. Qin F, Yan C, Patel R, Liu W, Dong E. Vitamins C and E attenuate apoptosis, beta-adrenergic receptor desensitization, and sarcoplasmic reticular Ca2+ ATPase downregulation after myocardial infarction. Free Radic Biol Med. May 15 2006;40(10):1827–1842
  78. Shi W, Meininger CJ, Haynes TE, Hatakeyama K, Wu G. Regulation of tetrahydrobiopterin synthesis and bioavailability in endothelial cells. Cell Biochem Biophys. 2004;41:415–434
  79. Enstrom JE, Kanim LE, Klein MA. Vitamin C intake and mortality among a sample of the United States population. Epidemiology. 1992;3:194–202
  80. MRC/BHF Heart Protection Study of antioxidant vitamin supplementation in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet. 2002;360:23–33
  81. Erbs S, Gielen S, Linke A, et al. Improvement of peripheral endothelial dysfunction by acute vitamin C application: different effects in patients with coronary artery disease, ischemic, and dilated cardiomyopathy. Am Heart J. Aug 2003;146(2):280–285
  82. Seligmann H, Halkin H, Rauchfleisch S, et al. Thiamine deficiency in patients with congestive heart failure receiving long-term furosemide therapy: a pilot study. Am J Med. 1991;91:151–155
  83. Zenuk C, Healey J, Donnelly J, Vaillancourt R, Almalki Y, Smith S. Thiamine deficiency in congestive heart failure patients receiving long-term furosemide therapy. Can J Clin Pharmacol. 2003;10:184–188
  84. Brady JA, Rock CL, Horneffer MR. Thiamin status, diuretic medications, and the management of congestive heart failure. J Am Diet Assoc. 1995;95:541–544
  85. Kwok T, Falconer-Smith JF, Potter JF, Ives DR. Thiamine status of elderly patients with cardiac failure. Age Ageing. 1992;21:67–71
  86. Pfitzenmeyer P, Guilland JC, d'Athis P, Petit-Marneier C, Gaudet M. Thiamine status of elderly patients with cardiac failure including the effects of supplements. Int J Vitam Nutr Res. 1994;64:113–118
  87. Yue QY, Beerman B, Lindstrom B, Nyquist O. No difference in blood thiamine diphosphate levels between Swedish Caucasians patients with congestive heart failure treated with furosemide and patients without heart failure. J Intern Med. 1997;242:491–495
  88. Mendoza CE, Rodriguez F, Rosenberg DG. Reversal of refractory congestive heart failure after thiamine supplementation: a case report and review of the literature. J Cardiovasc Pharmacol Ther. 2003;8:313–316
  89. Arsenian MA. Carnitine and its derivatives in cardiovascular disease. Prog Cardiovasc Dis. 1997;40:265–286
  90. Schonekess BO, Allard MF, Lopaschuk GD. Propionyl l-carnitine improvement of hypertrophied heart function is accompanied by an increase in carbohydrate oxidation. Circ Res. 1995;77:726–734
  91. Engel AG, Rebouche CJ. Carnitine metabolism and inborn errors. J Inherit Metab Dis. 1984;7(Suppl 1):38–43
  92. Pepine CJ. The therapeutic potential of carnitine in cardiovascular disorders. Clin Ther. 1991;13:2–18
  93. Whitmer JT. l-carnitine treatment improves cardiac performance and restores high-phosphate pools in cardiomyopathic Syrian hamster. Circ Res. 1987;61:396–408
  94. Iliceto S, Scrutinio D, Bruzzi P, et al. Effects of l-carnitine administration on left ventricular remodeling after acute anterior myocardial infarction: the l-Carnitine Ecocardiografia Digitalizzata Infarto Miocardico (CEDIM) Trial. Am Coll Cardiol. 1995;26:380–387
  95. Risos I. Three-year survival of patients with heart failure caused by dilated cardiomyopathy and l-carnitine administration. Am Heart J. 2000;139:S120–S123
  96. Nascimben L, Ingwall JS, Pauletto P, et al. Creatine kinase system in failing and nonfailing human myocardium. Circulation. 1996;94:1894–1901
  97. Neubauer S, Horn M, Cramer M, et al. Myocardial phosphocreatine-to-ATP ratio is a predictor of mortality in patients with dilated cardiomyopathy. Circulation. 1997;96:2190–2196
  98. Pulido SM, Passaquin AC, Leijendekker WJ, et al. Creatine supplementation improves intracellular Ca2+ handling and survival in mdx skeletal muscle cells. FEBS Lett. 1998;439:357–362
  99. Balsom PD, Soderlund K, Ekblom B. Creatine in humans with special reference to creatine supplementation. Sports Med. 1994;18:268–280
  100. Casey A, Constantin-Teodosiu D, Howell S, et al. Creatine ingestion favorably affects performance and muscle metabolism during maximal exercise in humans. Am J Physiol. 1996;271:E31–E37
  101. Andrews R, Grenhaff P, Curtis S, Perry A, Cowley AJ. The effect of dietary creatine supplementation on skeletal muscle metabolism in congestive heart failure. Eur Heart J. 1998;19:617–622
  102. Weisshaar RE, Simpson RU. Involvement of vitamin D3 with cardiovascular function. Direct and indirect effects. Am J Physiol. 1987;253:E675–E683
  103. Witte KK, Desilva R, Chattopadhyay S, Ghosh J, Cleland JG, Clark AL. Are hematinic deficiencies the cause of anemia in chronic heart failure?. Am Heart J. May 2004;147:924–930
  104. Gorelik O, Almoznino-Sarafian D, Feder I, et al. Dietary intake of various nutrients in older patients with congestive heart failure. Cardiology. 2003;99:177–181
  105. Andersson SE, Edvinsson ML, Edvinsson L. Reduction of homocysteine in elderly with heart failure improved vascular function and blood pressure control but did not affect inflammatory activity. Basic Clin Pharmacol Toxicol. 2005;97:306–310
  106. Andersson SE, Edvinsson ML, Edvinsson L. Reduction of homocysteine in elderly with heart failure improved vascular function and blood pressure control but did not affect inflammatory activity. Basic Clin Pharmacol Toxicol. 2005;97:306–310
  107. Wester PO, Dyckner T. Intracellular electrolytes in cardiac failure. Acta Med Scand Suppl. 1986;707:33–36
  108. Milionis HJ, Alexandrides GE, Liberopoulos EN, Bairaktari ET, Goudevenos J, Elisaf MS. Hypomagnesemia and concurrent acid-base and electrolyte abnormalities in patients with congestive heart failure. Eur J Heart Fail. 2002;4:167–173
  109. Cohen N, Almoznino-Sarafian D, Zaidenstein R, et al. Serum magnesium aberrations in furosemide (frusemide) treated patients with congestive heart failure: pathophysiological correlates and prognostic evaluation. Heart. 2003;89:411–416
  110. Haigney MC, Berger R, Schulman S, et al. Tissue magnesium levels and the arrhythmic substrate in humans. J Cardiovasc Electrophysiol. 1997;8:980–986
  111. Gottlieb SS, Baruch L, Kukin ML, et al. Prognostic importance of the serum magnesium concentration in patients with congestive heart failure. J Am Coll Cardiol. 1990;16:827–831
  112. Eichorn EJ, Tandon PK, Di Bianco R. Clinical and prognostic significance of serum magnesium concentration in patients with severe CCF: the PROMISE study. J Am Coll Cardiol. 1993;21:634–640
  113. Wester PO. Electrolyte balance in heart failure and the role for magnesium ions. Am J Cardiol. 1992;70:44–49C
  114. Gottlieb SS. Importance of magnesium in congestive heart failure. Am J Cardiol. 1989;63:39–42G
  115. Strassburger M, Bloch W, Sulyok S, et al. Heterozygous deficiency of manganese superoxide dismutase results in severe lipid peroxidation and spontaneous apoptosis in murine myocardium in vivo. Free Radic Biol Med. 2005;38:1458–1470
  116. Golik A, Zaidenstein R, Dishi V, et al. Effects of captopril and enalapril on zinc metabolism in hypertensive patients. J Am Coll Nutr. 1998;17:75–78
  117. Koren-Michowitz M, Dishy V, Zaidenstein R, et al. The effect of losartan and losartan/hydrochlorothiazide fixed-combination on magnesium, zinc, and nitric oxide metabolism in hypertensive patients: a prospective open-label study. Am J Hypertens. 2005;18:358–363
  118. Arthur JR, Nicol F, Mitchell JH, et al. Selenium and iodine deficiencies and selenoprotein function. Biomed Environ Sci. 1997;10:129–135
  119. Levander OA. A global view of human selenium nutrition. Annu Rev Nutr. 1987;7:227–250
  120. Schnabel R, Lackner KJ, Rupprecht HJ, et al. Glutathione peroxidase 1 activity and homocysteine for cardiovascular risk prediction. Results from the Athero Gene Study. J Am Coll Cardiol. 2005;45:1631–1637
  121. Wu HY, Xia YM, Ha PC, Chen XS. Changes in myocardial thyroid hormone metabolism and alpha-glycerophosphate activity in rats deficient in iodine and selenium. Br J Nutr. 1997;78:671–676
  122. Blankenberg S, Rupprecht HJ, Bickel C, et al. Glutathione peroxidase activity and cardiovascular events in patients with coronary artery disease. N Engl J Med. 2003;349:1605–1613
  123. Reeves WC, Marchuard SP, Willis SE, et al. Reversible cardiomyopathy due to selenium deficiency. J Parent Enter Nutr. 1989;13:663–665
  124. Kien CL, Ganther HE. Manifestations of chronic selenium deficiency in a child receiving total parenteral nutrition. Am J Clin Nutr. 1983;37:319–321
  125. Gramm HJ, Kopf A, Brätter P. The necessity of selenium substitution in total parenteral nutrition and artificial alimentation. J Trace Elem Med Biol. 1995;9:1–12
  126. Darling G, Mathias P, Oregan M, et al. Serum selenium levels in individuals on PKU diets. J Inherit Metab Dis. 1991;87:339

☆ Supported by NIH NHLBI grant RO1 HL53392 and the Children's Cardiomyopathy Foundation, Inc.

PII: S1058-9813(07)00081-1

doi: 10.1016/j.ppedcard.2007.08.007

Progress in Pediatric Cardiology
Volume 24, Issue 1 , Pages 59-71 , November 2007

Article Tools

* Image Usage & Resolution